These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20020572)

  • 1. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasofoxifene for postmenopausal women with osteoporosis.
    Malozowski S
    N Engl J Med; 2010 Jun; 362(23):2227; author reply 2228-9. PubMed ID: 20558377
    [No Abstract]   [Full Text] [Related]  

  • 4. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C
    N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
    [No Abstract]   [Full Text] [Related]  

  • 5. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
    N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not all SERMs are created equal.
    Goldstein SR
    Menopause; 2006; 13(3):325-7. PubMed ID: 16735926
    [No Abstract]   [Full Text] [Related]  

  • 7. Lasofoxifene for postmenopausal women with osteoporosis.
    Silva-Fernández L; Andreu JL
    N Engl J Med; 2010 Jun; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lasofoxifene in osteoporosis and its place in therapy.
    Swan VJ; Hamilton CJ; Jamal SA
    Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 11. Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
    Brandi ML
    Curr Med Res Opin; 2010 Nov; 26(11):2553-63. PubMed ID: 20858031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibandronic acid IV: new formulation. Unconvincing evidence.
    Prescrire Int; 2008 Feb; 17(93):10. PubMed ID: 18354845
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of bone quality. Bone quality and osteoporosis treatment].
    Mashiba T
    Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long term effects of raloxifen on the bones].
    Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):224-6. PubMed ID: 18282451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Peterson GM; Naunton M; Tichelaar LK; Gennari L
    Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
    Archer DF
    Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
    [No Abstract]   [Full Text] [Related]  

  • 20. Lasofoxifene (Pfizer).
    Gennari L
    Curr Opin Investig Drugs; 2005 Oct; 6(10):1067-78. PubMed ID: 16259229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.